Aqemia to Participate in Jefferies European Disruptive Tech Conference

Contributed by: Business Wire

Logo

Images

Maximilien_Levesque_CEO_Aqemia.

Business Wire embedded0

Tags

Health Technology

Technology

Nanotechnology

Finance

Pharmaceutical

Oncology

Professional Services

Neurology

Artificial Intelligence

Cardiology

Science

Biotechnology

Software

Health

Research

European Disruptive Tech Conference

More Like This

Maximilien Levesque, CEO and Cofounder of AQEMIA (left) and Emmanuelle Martiano Rolland, COO and Cofounder of AQEMIA (Photo: Business Wire)

AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK

AQEMIA FOUNDERS - Maximilien Levesque (CEO) and Emmanuelle Martiano (COO)

Aqemia Advances Epitranscriptomics Programs and Expands into Small-Molecule RNA Targeting with $7.4 Million Grant

AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for clinical, industrial and research applications (Graphic: Sequentia Biotech)

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications

PR Newswire associated0

AZmed Secures €15 Million to Shape the Future of Medical Imaging with AI

Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)

PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science

Exscientia to Present at Upcoming Investor Conferences in June

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development